Taysha Gene Therapies, Inc. Balance Sheet
TSHA / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Taysha Gene Therapies, Inc. had $343M in total assets and $247M in shareholders' equity as of FY2025. Total debt was $50M against $320M in cash, resulting in a $270M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M | $251.3M |
| Current Assets | $324.6M | $142.1M | $149.9M | $96.4M | $159.6M | $257.9M |
| PP&E (Net) | $6.7M | $7.5M | $10.8M | $15.0M | $50.6M | $287.0K |
| Total Assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M |
| Current Liabilities | $26.6M | $26.2M | $36.8M | $62.8M | $51.7M | $7.1M |
| Total Debt | $50.1M | $43.9M | $40.5M | $38.0M | $37.2M | - |
| Shareholders' Equity | $246.9M | $74.9M | $949.0K | $95.4M | $95.4M | $251.3M |